In Vivo's Deals Of The Month, October 2016
In Vivo's editors pick October's most significant deals, including stealthy Carrick's big Series A and AstraZeneca's out-licensing spree. (Article free with registration.)
You may also be interested in...
AstraZeneca concludes week of four out-licensing transactions by selling US rights to Toprol XL to Aralez and ex-US rights to Rhinocort Aqua to J&J. Molecular Partners gets back rights to an IL-13/IL-17 inhibitor for pulmonary indications after a 2011 deal with Janssen unravels.
Continuing its strategy to exit non-core activities, AstraZeneca's licensed Allergan global rights to its IL-23 monoclonal antibody in Phase IIb testing for moderate-to-severe Crohn’s disease and ready for Phase II studies in ulcerative colitis. Analysts say the deal makes sense for both parties.
With $95m in the bank from various investors – including ARCH Ventures, Woodford Investment Management, Google Ventures and drug discovery company Evotec – recently launched Carrick Therapeutics is striving to be at the forefront of oncology companies in Europe.